Intestinal permeability in patients with metastatic colon cancer treated with patupilone

Melichar, Bohuslav; Hyšpler, Radomı́r; Tichá, Alena; Kalábová, Hana; Vitásková, Denisa; Zezulová, Michaela; Dvořák, Josef; Cerman, Jaroslav; Doležel, Martin

doi:10.1515/cclm-2014-0096

Cited by 8 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different laboratory methods have been proposed for monitoring of gastrointestinal toxicity of anticancer agents. Despite promising results, the measurement of intestinal permeability is difficult to be performed in practice (115,116). Citrulline represents another potential biomarker of intestinal toxicity of chemotherapy or radiation.…”

Section: Neopterin and Toxicity Of Anticancer Therapymentioning

confidence: 99%

Neopterin as a biomarker of immune response in cancer patients

Melichar¹,

Spisarová²,

Bartoušková³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

Section: Neopterin and Toxicity Of Anticancer Therapymentioning

confidence: 99%

Neopterin as a biomarker of immune response in cancer patients

Melichar¹,

Spisarová²,

Bartoušková³

et al. 2017

Ann. Transl. Med.

Self Cite

View full text Add to dashboard Cite

“…While laboratory methods can determine peripheral blood cell count as continuous variables allowing for a graded assessment and differential response to the changes induced by the treatment, the assessment of gastrointestinal toxicity still depends almost exclusively on the data reported by the patients that may be affected by subjective factors and are often impossible to verify. Different laboratory biomarkers have been introduced in the assessment of gastrointestinal toxicity of systemic anticancer agents, including the measurement of intestinal permeability or monitoring of citrulline concentrations, as in the present report [11,[24][25][26]. Despite promising results of intestinal permeability, this method is not well suited for routine clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract:We report a patient who presented with synchronous second primary human epidermal growth factor receptor (HER)-2-positive breast cancer and rectal cancer that both required simultaneous neoadjuvant therapy. A modified regimen combining anti-HER-2 monoclonal antibody trastuzumab with chemotherapy and external beam radiation was selected. An organ-preserving surgical procedure was possible both in the breast and the rectum. Citrulline decreased rapidly after the start of the treatment, and then gradually returned to pre-treatment levels after the completion of chemoradiation. Urinary neopterin concentrations exhibited a fluctuating course. Both serum neopterin and C-reactive protein concentrations were more or less stable during the initial administration of trastuzumab, paclitaxel and carboplatin and then increased steeply during chemoradiation and subsequently declined to pre-treatment levels during the weekly trastuzumab administration. Changes were observed in the serum retinol concentrations. A decline in lymphocyte counts was accompanied by marked changes in peripheral blood cell count-derived ratios. The present case report demonstrates a successful combination of two neoadjuvant regimens in a patient with two synchronous different second primary tumors. Data from this case also illustrate the use of biomarkers for monitoring of intensive therapeutic regimens in medical and radiation oncology.

show abstract

“…For example, in another study in patients with early colorectal cancer the prognostic nutritional index and carbohydrate antigen 19-9 concentration, but none of the PBC-derived ratios were significant predictors of prognosis [50]. Aside from the measurement of PBC, the role of laboratory medicine in predicting or monitoring other important side effects of systemic treatment like gastrointestinal toxicity is more limited [51][52][53]. The biomarkers of inflammatory response may predict both the prognosis and complications of therapy [51,54], but more research should be dedicated to this topic.…”

Section: Discussionmentioning

confidence: 99%

Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract:The aim of the present study was to investigate the association of peripheral-blood cell count (PBC)-derived ratios, other biomarkers of inflammation and biomarkers of tumor growth with outcome in a cohort of patients presenting for the next line of therapy after the failure of prior systemic treatment. The data of 51 patients with advanced/metastatic colorectal carcinoma treated with cetuximab in the second or higher line of therapy were retrospectively analyzed. The median duration of cetuximab therapy and the median survival were 5.1 and 12.1 months, respectively. C-reactive protein (CRP), but not urinary neopterin correlated significantly with PBC-derived ratios. Both CRP and urinary neopterin correlated positively with carcinoembryonic antigen (CEA) concentrations and biomarkers of liver dysfunction. Although a number of parameters predicted overall survival in univariate analysis, only hemoglobin, CEA change and serum bilirubin were independent predictors of survival. In conclusion, in patients with metastatic colorectal carcinoma and predominantly liver metastases, the outcome of therapy in the advanced line setting was associated with initial hemoglobin level, a decrease of CEA concentration and initial presence of liver dysfunction. Urinary neopterin did not correlate with PBC-derived ratios, in contrast to CRP, but both urinary neopterin and serum CRP concentrations correlated with laboratory parameters of liver dysfunction.

show abstract

Intestinal permeability in patients with metastatic colon cancer treated with patupilone

Abstract: Measurement of intestinal permeability using the lactulose/mannitol test may represent a biomarker for the monitoring, or even prediction of toxicity of cytotoxic drugs, including patupilone.

Cited by 8 publications

References 13 publications

Neopterin as a biomarker of immune response in cancer patients

Neopterin as a biomarker of immune response in cancer patients

Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study

Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab

Contact Info

Product

Resources

About